Plain-English translation of NCT07151378 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a medication called Lecigon®, which delivers Parkinson's medicine directly into the intestines rather than taking it by mouth. Researchers want to see whether this medication can better control difficult mood and behavior changes that sometimes happen when people take Parkinson's medications for many years. The study will compare Lecigon® to the best available oral (by mouth) Parkinson's treatments currently available.
Over time, some people with Parkinson's disease develop troubling mood and behavior changes—like impulsive or unusual behavior—from their long-term medications. This trial exists to see whether delivering the medication differently through the intestines might reduce these side effects while still controlling Parkinson's symptoms effectively.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to either continue your current oral Parkinson's medications or to start using the new Lecigon® medication. The study will track you for 6 months, with visits to assess how well your symptoms (especially mood and behavior) are controlled. Researchers will use standardized questionnaires and rating scales to measure changes in your symptoms over time.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
Germany